克服CXCR4介导的T细胞排斥可增强纤维板层癌的抗肿瘤细胞毒性
本研究探讨纤维板层癌(FLC)免疫治疗抵抗机制,采用单核RNA测序、多重免疫组化、活细胞成像、单细胞测序和空间蛋白组学及人肿瘤切片培养(TSC)系统。发现CXCL12+肌成纤维细胞与CXCR4+淋巴细胞相互作用介导T细胞排斥,CXCR4抑制联合PD-1阻断在TSC模型中显著增加肿瘤细胞死亡,优于单药治疗。
要点
- FLC免疫抵抗由T细胞排斥和耗竭双重机制介导。
- CXCR4抑制可动员基质T细胞进入癌巢。
- CXCR4联合PD-1阻断协同增强抗肿瘤效果。
核心结论
- FLC免疫抵抗由局部T细胞排斥和耗竭共同介导,CXCR4与PD-1联合阻断协同克服这两种独立机制。
研究设计与样本
- 采用高通量单核RNA测序探索FLC肿瘤免疫微环境,并利用多重免疫组化、活细胞成像、单细胞测序和空间蛋白组学在人肿瘤切片培养(TSC)系统中验证和调控。
主要发现
- FLC肿瘤免疫微环境中基质-免疫信号通路显著失调,突出表现为CXCL12+肌成纤维细胞与CXCR4+淋巴细胞的相互作用。
- CXCR4抑制足以将基质T细胞动员至癌巢区域,添加PD-1阻断可独立激活T细胞抗肿瘤效应功能。
- 在人TSC模型中,CXCR4与PD-1联合阻断较任一单药治疗显著增加肿瘤细胞死亡。
关键数值与推荐
- CXCR4抑制联合PD-1阻断在人TSC模型中较单药显著增加肿瘤细胞死亡。
临床怎么用
- 为FLC这一缺乏有效系统治疗的罕见肝癌提供合理组合免疫治疗设计的临床前证据。
- 人TSC系统可用于罕见癌症类型的研究。
局限性
- 研究基于临床前模型(人肿瘤切片培养系统),尚未在临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fibrolamellar carcinoma (FLC) is a rare liver cancer affecting young adults without underlying cirrhosis. Although almost all FLC patients share an immunogenic DNAJB1-PRKACA fusion oncogene, endogenous antitumor immunity and clinical response to immunotherapy are limited. We hypothesized that the lack of response to immunotherapy is mediated by both T-cell exclusion and intratumoral immunosuppression. METHODS: We used high-throughput single-nucleus RNA sequencing to explore the tumor immune microenvironment (TIME) of FLC. We then used multiplex immunohistochemistry, live imaging, single-cell sequencing, and spatial proteomics in a human tumor slice culture (TSC) system to dissect and experimentally modulate the FLC TIME. RESULTS: We identified significant dysregulation of stromal-immune signaling pathways within the FLC TIME relative to adjacent nontumor liver, notably including interactions between CXCL12+ myofibroblasts and CXCR4+ lymphocytes. CXCR4 inhibition was sufficient to mobilize stromal T cells into the carcinoma compartment, with the addition of PD-1 blockade independently activating T-cell antitumor effector function. Combination CXCR4 and PD-1 blockade resulted in a significant increase in tumor cell death relative to either treatment alone in a human TSC model. CONCLUSIONS: Our findings demonstrate that immune resistance in FLC is mediated by both local T-cell exclusion and exhaustion, with combination CXCR4 and PD-1 blockade acting cooperatively to overcome these independent mechanisms. These results highlight the versatility of the human TSC system to aid in the study of rare cancer types and provide important preclinical evidence for the rational design of combination immunotherapy in FLC, which currently lacks any effective systemic therapy.
引用
- Carter JA, Dickerson LK, Stephanou A, et al. Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma. Gastroenterology. 2026. PMID: 41701126. doi:10.1053/j.gastro.2025.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。